Other Infections
Naloxone Is Cost-effective Way to Prevent Heroin Overdose Deaths
- Details
- Category: People Who Inject Drugs
- Published on Thursday, 03 January 2013 00:00
- Written by Liz Highleyman
Distributing naloxone more widely to heroin users would reduce the number of deaths due to overdose and would be a cost-effective intervention, according to a mathematical model described in the January 1, 2013,Annals of Internal Medicine. Providing naloxone to prescription opiate users would prevent even more deaths.
Bedaquiline Approved for Multidrug-resistant Tuberculosis after Long Wait
- Details
- Category: Tuberculosis (TB)
- Published on Thursday, 03 January 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration last week approved bedaquiline (brand name Sirturo, formerly TMC207) as part of a combination regimen for adults with multidrug-resistant pulmonary tuberculosis (TB) -- the first approval of a new TB drug in more than 40 years.
Human Papillomavirus Vaccination Can Protect Many Women with HIV
- Details
- Category: Human Papillomavirus (HPV)
- Published on Monday, 12 November 2012 00:00
- Written by Liz Highleyman
HIV positive women may benefit from immunization against cancer-causing human papillomavirus (HPV) types, even though they are likely to have been exposed to some types of the virus previously, according to a study in the November 1, 2012, Journal of Acquired Immune Deficiency Syndromes. A majority of study participants remained susceptible to the most common high-risk types, HPV-16 and HPV-18.
2012-2013 Could Be Bad Flu Season, Not Too Late to Get Vaccine, CDC Advises
- Details
- Category: Influenza
- Published on Tuesday, 04 December 2012 00:00
- Written by Liz Highleyman
Significant increases in influenza activity in the U.S. during the past 2 weeks indicate that this year's flu season has come early, and it could be a bad one, according to the Centers for Disease Control and Prevention (CDC). December 2-8 is National Influenza Vaccination Week, and it's not too late to get yours.
Topical Cidofovir Effective and Well-tolerated for Anal and Vulva Neoplasia
- Details
- Category: Human Papillomavirus (HPV)
- Published on Friday, 26 October 2012 00:00
- Written by Liz Highleyman
A topical formulation of the antiviral drug cidofovir (Vistide), best known as a treatment for cytomegalovirus (CMV), also appears effective for short-term treatment of high-grade anal and vulva cancer caused by human papillomavirus (HPV) in people with HIV, according to a report in the October 1, 2012, advance online edition of AIDS. 
FDA Committee Supports Accelerated Approval of TB Drug Bedaquiline
- Details
- Category: Tuberculosis (TB)
- Published on Friday, 30 November 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee this week gave a favorable opinion on Janssen's request for accelerated approval of its investigational tuberculosis drug bedaquiline (also known as Sirturo, formerly TMC207) for treatment of multidrug-resistance TB (MDR-TB).
WHO: TB Rates Fall, but Drug Resistance Still a Concern
- Details
- Category: Tuberculosis (TB)
- Published on Tuesday, 23 October 2012 00:00
- Written by Press Release
Rates of new tuberculosis (TB) cases and deaths have declined and approximately 20 million people worldwide are alive due to TB care and control efforts, but too little is being done to address multidrug-resistant TB, according to the World Health Organization's Global Tuberculosis Report 2012.
ICAAC 2012: Cobicistat-boosted Elvitegravir Does Not Interact with Methadone
- Details
- Category: HIV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
The new HIV integrase inhibitor elvitegravir, boosted with cobicistat, does not cause clinically important changes in levels of methadone or buprenorphine used to manage opiate addiction, researchers reported at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco.
CDC Recommends Pneumococcal Vaccine Combo for Immune Compromised People
- Details
- Category: Opportunistic Illness (OIs)
- Published on Tuesday, 16 October 2012 00:00
- Written by Liz Highleyman
Immunocompromised individuals, including people with HIV, should receive both the 13-valent pneumococcal conjugate vaccine Prevnar 13 and the 23-valent pneumococcal polysaccharide vaccine Pneumovax 23 to prevent pneumococcal pneumonia and invasive disease, according to the latest recommendations from the Centers for Disease Control and Prevention (CDC). 
More Articles...
- Adding Delamanid to Combination Regimen Reduces Risk of Death for People with Resistant TB
- Retrovirus XMRV Not Linked to Chronic Fatigue or Prostate Cancer
- WHO Issues New Coronavirus Alert, Says It Does Not Spread Easily Like SARS
- ICAAC 2012: Are Statins Beneficial for Patients with Candida Fungal Infections?
- Study Shows Extensively Drug-resistant TB is Becoming More Common Worldwide
Web Design and Development by